The test is based on glycosylated hemoglobin (HbA1c) as a marker, which is preoteolytically digested and selectively oxidized by a proprietary fructosyl peptide oxidase developed by Kikkoman. The procedure won a prize at the 22nd Annual Meeting of the Japanese Society for Fermentation and Bioengineering presently held in Hiroshima.

Kikkoman press release, Sept. 12, 2013